Researchers develop new non-invasive test for early detection of urothelial cancer

NewsGuard 100/100 Score

Urothelial cancers of the bladder and upper urinary tract are among the most common cancers encountered worldwide. In the United States, urothelial cancers are among the most costly cancers to treat. With early diagnosis, followed by surgery, most urothelial cancers can be cured. Now an international team of cancer researchers including Kate Dickman, PhD, of the Department of Pharmacological Sciences and Medicine/Nephrology at Stony Brook University School of Medicine have developed a highly sensitive and specific non-invasive test as a biomarker for early detection of urothelial cancers. Details of this method known as UroSEEK, are published in eLife.

UroSEEK identifies genetic errors in cells shed into urine. The analysis scans for mutations in 11 cancer driver genes associated with urinary tract cancer and for evidence of chromosomal imbalance.

In the study, the researchers found that of 570 patients at risk for bladder cancer, UroSEEK tested positive in 83 percent of those who developed bladder cancer. The detection rate increased to 95 percent when urine cytology and UroSEEK were used in combination. They found also that of 56 patients with upper tract urothelial cancer, 75 percent tested positive by UroSEEK. In the future, the researchers say, UroSEEK will be applied to large patient populations to screen for bladder and upper urothelial cancer.

Source: https://www.stonybrook.edu/newsroom/general/2018-03-30-New-Non-Invasive-Test-for-Urothelial-Cancer.php

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Lancet Commission on Breast Cancer: Transforming breast cancer care globally